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Summary The histological breakdown of a consecutive series of 264 surgically resected malignant lesions of
the breast was studied. Oestrogen and epidermal growth factor receptor status was quantified and presented
along with size and lymph node status of the non-ductal lesions. Those non-ductal tumours containing EGF
receptors have all recurred within two years of resection. Twenty-one percent of the lobular carcinomas
contained EGF receptors compared to 34% of ductal carcinomas. EGF receptor status appeared to be
associated with an increased risk of early recurrence and death whatever the histological sub-type of the
breast cancer.
Many prognostic variables have been described for use in the
study of breast cancer. Patient variables (such as age at
menarche or parity) and clinical findings (such as palpable
lymph nodes) give useful information.
Study of the resected specimen allows assessment of
further variables. Size of the lesion is most accurately
measured by the pathologist as is the involvement of lymph
nodes with tumour. Various histological scoring systems
have been described, the best known of which is the Bloom
and Richardson grade (1957). It was originally described for
invasive ductal tumours but is sometimes used for other
histological variants.
The histological subtype of breast cancer is itself of
prognostic value. The currently accepted histological break-
down of tumour types is shown in Table I. Better long term
survival has been attributed to tubular and mucinous lesions
and worse to invasive lobular and inflammatory carcinomas
(Dixon et al., 1985).
Receptors for steroid hormones such as oestrogen and
progesterone are also prognostic indicators (Jensen et al.,
1967; McGuire et al., 1968; Howell et al., 1984). Tumours
rich in oestrogen receptor (ER) are more likely to respond to
endocrine therapy at relapse as well as taking longer to
relapse (Howell et al., 1984). They are also likely to recur in
'more favourable' sites such as bone rather than liver and
brain (Stewart et al., 1980). The expression of progesterone
receptor (PR) is said to indicate that the ER is functionally
active and presence of both receptors gives the most favour-
able outcome (Horwitz & McGuire, 1978).
Receptors for other hormones have been identified but are
less well studied. Prolactin (Shiu, 1979), growth hormone
(Murphay et al., 1984) and insulin receptors (Benson &
Holdaway, 1981) have all been described. Epidermal growth
factor receptors (EGFr) on human breast cancer cells have
also been described both for derived cell lines (Fitzpatrick et
al., 1984a) and resected specimens (Sainsbury et al., 1985a,
Fitzpatrick et al., 1984b). EGF is a polypeptide similar to
urogastrone. In common with transforming growth factor
alpha (TGFx), it binds to the EGFr. Part of the EGFr is
similar in structure to the erb-B oncoprotein (Downward et
al., 1984). TGFax is secreted by breast cancer cells (Salomon
et al., 1987) and an autocrine self-stimulatory role has been
postulated (Dickson et al., 1986). There is an inverse rela-
tionship between EGFr and ER (Sainsbury et al., 1985b),
and the presence of EGFr is associated with higher Bloom
and Richardson grades (Sainsbury et al., 1985c) and worse
patient survival (Sainsbury et al., 1987). EGFr is a better
prognostic variable than oestrogen receptor.
A recent report examined the relationship of EGFr with
histological type of breast cancer. Skoog et al. (1986) found
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that whilst 8 of 22 (28%) ductal carcinomas and 2 of 2
medullary carcinomas had EGFr none could be found on
nine lobular or four colloid lesions. This series was retros-
pective using stored tissue and it is not clear to what extent
the specimens used for analysis were selected. As such this
may represent an atypical population.
Since EGFr status is a predictor of poor outcome we
assessed whether there were differences in EGFr expression
that could be related to differences in histological sub-type.
We present a series of 264 consecutive surgically resected
breast cancer specimens with an analysis of histological type
and EGFr and ER status.
Materials and methods
Tumours were collected fresh from theatre and processed
immediately. Sections were taken for histological study and
immuno-histochemistry and the remainder of the tissue used
to assay ER and EGFr by radioligand binding methods. ER
levels were determined by a dextran coated charcoal tech-
nique (Maynard & Griffiths, 1979) and EGFr by radioligand
binding (Sainsbury et al., 1985a; Nicholson et al., 1988).
The cut off point used to determine EGFr positivity was
lOfmolmg-1 membrane protein (Nicholson et al., 1988) and
also lOfmolmg-1 cytosolic protein for ER positivity.
The x2 test was used to analyse the results with Yate's
modification if numbers were < 10 per cell or 100 in total.
Results
Twenty-five (9%) non-ductal carcinomas were identified in
this series of 264 breast cancers. The breakdown of their
histology is shown in Table II along with EGFr and ER
status, size and lymph node status.
Fourteen (56%) were lobular carcinomas of which 3
Table I Histological types of breast cancer.
Invasive
Infiltrating ductal NOS (not otherwise specific)
Lobular invasive
Medullary
Mucinoid
Tubular
Adenocystic
Papillary
Carcinosarcoma
Mixed histologies
Non-invasive
Lobular carcinoma in situ
Ductal carcinoma in situ
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Table II Histology, EGF receptor and oestrogenreceptor status,
size and lymph node status of 25 non-ductal breast cancers.
Lymph
Size node
EGFr ER (cm) status
Lobular n= 14 + - 3.3
+ - 2.0 2/3
+ - 4.5
(21% EGFr +ve) - + 3.5
- + 2.0
- + 5.0 1/2
- + 9.0 6/7
- + 2.5
- + 3.0 1/5
- - 1.4
- - 8.0 1/1
- - 0.7
- - 4.0 6/6
- - 2.5 6/6
Mucoid n=3 + - 4.1
- + 5.1
- - 2.5 1/16
Tubular n=3 - + 2.4
- + 1.8 1/5
_ + 1.5
Cystosarcoma phylloides + - 14.0
- + 10.5
Clear cell - - 2.5
Carcinoid - + 1.7 3/3
Fibrosarcoma - - 3.5
n=25 5 EGFr +ve 12 ER +ve
Table III Relationship of EGF receptor and oestro-
gen receptor for ductal and lobular cancers.
EGFr
Positive Negative
Ductal
ER positive 10 84
negative 71 74
239
x2=35.7; P<0.001
Lobular
ER positive 0 6
negative 3 5
14
Histology
Ductal 81 158
Lobular 3 11
253
x2=0.44; P=0.5
(21%) had EGFr (all ER negative), 6 (43%) were ER
positive (and EGFr negative) and the remaining 5 were
negative for both receptors. All three tubular lesions were
ER positive and EGFr negative. The cystosarcoma phyl-
loides lesions had undergone sarcomatous change - one was
EGFr+, ER- and the other ER+, EGFr-.
The previously reported finding of an inverse relationship
for the ductal lesions is shown in Table III along with the x2
analysis for lobular lesions. Thirty-four percent of these
lesions contained EGF receptors.
All the patients in the non-ductal group of tumours with
detectable EGFr have experienced recurrence within 2 years
of excision.
Discussion
The association of a worse outlook for patients with cancers
containing EGFr has been found for tumours of breast
(Sainsbury et al., 1987), bladder (Neal et al., 1985) and
stomach (Tahara et al., 1986). Only in the case of the uterus
is there a report of a better outcome (Hofman et al., 1984).
Although the highest expression of EGFr appears to be in
squamous carcinomas there are reports showing that EGFr
are found in approximately 35% of breast tumours. Several
studies have shown the inverse relationship between EGFr
and ER (Sainsbury et al., 1985b; Peres et al., 1984; Battaglia
et al., 1988).
Increased EGFr expression is associated with enhancement
of tumour growth when cell lines are implanted into nude
mice (Filmus et al., 1987). This enhanced growth is seen even
if nude mice are innoculated with EGFr positive cell lines
that do not secrete excess EGF or TGFa suggesting that
increased numbers of EGFr are sensitive, to endogenous,
background, growth factors. Some tumour cell lines do
secrete TGFa so there may be a mixture of autocrine and
paracrine stimulation. It has been postulated that the stroma
in which the epithelial cells sit may be releasing growth
factors. T47D cells secrete a PDGF-like substance which
may be responsible for the intense schirrous reaction seen
round some lesions (Rozengurt et al., 1985).
EGFr expression is related to markers of poor differentia-
tion and there is a correlation with higher Bloom and
Richardson scores for ductal carcinomas (Sainsbury et al.,
1985c).
Overexpression of other oncogenes is also related to poor
prognosis - there are recent reports of the neu oncogene
being overexpressed in tumours which relapsed early
(Slamon et al., 1987). There are preliminary data (Wright,
unpublished) showing that tumours staining positively for
neu are associated with early recurrence and death. This
finding was independent of EGFr status and the combi-
nation of neu positivity with EGFr increased the prognostic
power.
The histological sub-type of breast cancer allows the
pathologist to provide some indication of prognosis. Tubular
lesions, along with other tumours with special histological
features were found in patients who survived long term
whereas tumours with no special histological feature were
found in cases which died early. Cribriform tumours were
found in 13.4% oflong term survivors but in no patient who
died in under ten years whilst tumours of no special feature
were found in 27.7% of the long term survivors and in 83%
of those who died early (Dixon et al., 1985).
Our data, combined with those of Skoog et al. (1986),
suggest that the histologically high risk tumours are asso-
ciated with positive EGFr. It appears that EGFr positivity in
any histological subtype may be associated with poor prog-
nosis. Furthermore, these EGFr positive lesions are more
likely to recur early.
This work was supported by the North of England Cancer Research
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